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All countries in the European Community face common challenges
for delivering appropriate and high-quality care to patients with
cancer. However, despite tangible improvements in diagnosis and
treatment, marked differences in cancer survival across European
regions exist (Sant et al, 2001).
The translation of existing research results into consistent
patient-oriented strategies in the form of evidence reviews is a key
endeavour to help improve cancer care and patient outcomes.
Clinical practice guidelines (CPGs) are important tools for
informing health-care professionals and patients about appro-
priate clinical practice in cancer care. Numerous guidelines
development programmes have been set up in most European
countries to develop CPGs in various specialities, including
oncology (Courte ´-Wienecke et al, 1999).
However, recent studies have shown that published guidelines
vary in quality (Shaneyfelt et al, 1999; Grilli et al, 2000; Graham
et al, 2001) and some may even recommend suboptimal care. It has
been established that it is essential that CPGs are evidence-based,
so as to provide a valid tool for those caring for patients with
cancer. To be credible, CPGs should also be developed with the
input of local multidisciplinary cancer specialists (Ray-Coquard
et al, 1997, 2002) to encourage local acceptance and use in clinical
practice.
In addition to the process of development, guideline ‘after-care’,
i.e. the combination of dissemination, implementation and guide-
line updating, has been recognised as being important to the
success of guidelines (Browman, 2001a, b). Some oncology CPGs
have been shown to lead to significant changes in practice when
dissemination and implementation are conceptualised from the
beginning of the guideline development process (Ray-Coquard
et al, 1997, 2002; Fervers et al, 2001b).
The development, updating and implementation of high-quality
CPGs require substantial resources, both in terms of time and
money. Currently, there is no systemic and structured approach to
the development, evaluation and monitoring of guidelines at the
international level. Moreover, there is no infrastructure to sustain
and further develop these efforts. As a result, efforts are
unnecessarily duplicated by organisations in different countries
aiming at similar goals and using similar strategies. This may
result in the wastage of financial and structural resources, and the
suboptimal management of activities. These resources include the
time volunteered by experts who participate in the working
groups.
European countries could benefit from a multinational Eur-
opean collaboration for guidelines development, to minimise costs
and avoid existing unnecessary duplication of effort, and to
improve the dissemination and implementation of CPGs that
comply with internationally accepted quality criteria.
If a multinational collaboration for CPG development is to be set
up, it should be built on existing CPGs initiatives involved in the
development of CPGs in oncology. However, the CPGs initiatives
in different countries use different methodological approaches.
These differences can be explained, partly, by the differing reasons
for guideline development and the characteristics of organisations
involved in the CPG development process (Burgers et al, 2003).
One major difference, for example, is the choice between a ‘top
down’ strategy, organised by national (or regional) agencies, and a
‘bottom up’ strategy, based on professional initiative. Based on this
diversity, the experiences of the various initiatives are hetero-
geneous, as shown by an international survey of 19 guidelines
programmes. This situation yields a series of challenges that
should be addressed and also raises questions that must be
answered when setting up a multinational collaboration.
To ensure that CPGs will contribute to the improvement of care
for cancer patients, CPG development and the reporting of that
process should meet specific quality criteria (Grol et al, 2003). The
different dimensions of guideline quality that have been developed
and validated recently by the Appraisal of Guidelines, Research
and Evaluation (AGREE) Collaboration (funded under the
European Union Biomed II Research Programme) provide a
framework for the development of guidelines at the international
level (www.agreecollaboration.org). These dimensions include the
rigour of the methods used to collect and synthesise the evidence,
the process used to formulate the recommendations, the involve-
ment of stakeholders and the applicability of the recommenda-
tions.
Quality assessment of guidelines using the AGREE instrument
showed that CPGs produced as part of a structured programme
had significantly higher quality scores than those published
outside such programmes (AGREE Collaboration, 2003). As a
consequence, multinational cooperative projects could provide
appropriate infrastructure and the environment for sharing
specific tasks in the CPGs development and updating processes
as well as the dissemination and implementation processes. This
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procedures for sharing responsibilities.
A systemic approach is the basis for identifying which aspects of
the guidelines development process can be achieved in common
on a European or international level, and which aspects require
specific national and local input. Literature searching, critical
appraisal and synthesis of the evidence are key elements in the
guideline development and updating processes. They are also the
most costly and time-consuming steps in the path from research
results to evidence-informed recommendations. Although some of
the key elements in the guidelines development and updating
process should give consistent results, the cultural diversity among
European countries, particularly in terms of the structure and
organisation of care, can lead to legitimate variability in guideline
recommendations (Fervers et al, 1997; Eisinger et al, 1999). This
includes variations due to cost-considerations in reimbursement
strategies and policy-making decisions (Mille et al, 2000).
The collaboration between the guidelines project ‘Standards,
Options and Recommendations’ (SOR), run by the French
National Federation of Cancer Centres (FNCLCC) (Fervers et al,
2001a), the OECI (European Organisation of Cancer Centres) and
the Cancer Care Ontario Guidelines Initiative (CCOPGI) (Brow-
man et al, 1995) has provided good insight into the challenges
encountered when different countries cooperate. In particular, the
collaboration between the SOR and the CCOPGI has helped our
understanding of the legitimate reasons for discrepancies between
guideline recommendations based on the same evidence, due to
national and medical cultural differences (Browman, 2001a;
Fervers et al, 2001b; Burgers et al, 2003). However, further
research is needed to understand and to develop an explicit
approach for consideration of cultural and contextual considera-
tions in the formulation of the recommendations.
Multinational cooperation should ensure that shared guidelines
are relevant to national and local situations. This is crucial for the
successful implementation of the guidelines and can be achieved
by formulating the recommendations under national or local
responsibility. The involvement of national and local stakeholders
in the field of cancer from the participating countries will
contribute to the enhancement of the local pertinence and
acceptance of shared CPGs. The cultural diversity in Europe
highlights the need for a transparent and explicit guidelines
development process, in particular how recommendations are
produced, with a clear link between the evidence and the
recommendations, and information on how practitioners and
other stakeholders are involved in the process. A process based on
the Guidelines Development Cycle published by Browman et al
(1995) provides a means of achieving both generalisable evidence-
based recommendations and local relevance for practice (Figure 1).
To achieve the objectives of CPGs, multinational collaboration
should ensure accessibility of CPGs through appropriate dissemi-
nation and implementation strategies and by using different
formats. These strategies should be tailored to the different target
audiences involved in medical decision making (clinicians, policy
makers, patients and other citizens) and clinical settings in the
participating countries.
These observations, including the unnecessary duplication of
effort among existing guideline initiatives, have led to an
examination of how a multinational cooperative and structured
approach to guideline development and updating, dissemination
and implementation could be achieved in Europe (Fervers et al,
2002, http://eoi.cordis.lu/dsp_details.cfm?ID¼29033). In Europe,
as elsewhere, the reliability and sustainability of guidelines
development programmes is an unquestionable challenge. To
provide added value to existing guideline initiatives in Europe, the
proposed multinational collaboration should aim to share existing
experiences while taking into account the cultural and organisa-
tional diversity of the participating organisations and countries.
This is important if national relevance and acceptance by guideline
users are to be achieved, and if shared CPGs are to influence
clinical practice. This has been shown to be crucial for the
Canadian initiative when a national guidelines oncology pro-
gramme for approval of new drugs was set up, involving the
different provinces. In Europe, the different languages of the
various European countries will add a level of complexity to this
undertaking.
Promoting collaboration among guideline development initia-
tives in Europe will involve learning how we can build on existing
initiatives and how we can adopt common standards to improve
the consistency and quality of the guidelines. We will also have to
learn how to share CPG development and updating responsibilities
at an international level, and how to identify which responsibilities
should be delegated to the national and local levels. Also, we need
to learn how to increase the national relevance and local
acceptance of shared guidelines, how to identify appropriate
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Figure 1 Framework for shared development of evidence-based clinical practice guidelines with local relevance. Reprinted with permission from Elsevier
(The Lancet Oncology 2003; 4; 139–40)
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organisational framework for the shared development and
updating of CPGs. The process will also involve identifying
mechanisms for the development of related information for
patients and their families, cancer advocacy groups and other
citizens.
A proposal to set up a multinational collaboration for the
development of cancer clinical practice guidelines is currently
being elaborated. An outline proposal was submitted to the recent
call for ‘Expression of Interest’ that was launched by the European
union in the setting of its Sixth Framework programme for funding
research (http://www.cordis.lu/fp6/). This collaboration will in-
volve some members of the AGREE collaboration, a network of
health services, research institutions and guidelines development
organisations from 17 countries in Europe, USA, Canada and Asia-
Pacific countries, and some of the partners in a network of
European organisations working in the field of cancer, cancer
centres (via OECI), professional societies and cancer-care specia-
lists. This proposed multinational collaboration will make a
significant contribution to avoiding duplication of effort and
ensuring the availability of high-quality CPGs. This, in turn, will
give individual health professionals better access to modern
standards of clinical practice and thus contribute to improving
care for cancer patients. Enabling patients and other citizens to
understand cancer and its treatment better will improve their
quality of life and help them to learn to live better with cancer.
In addition, multinational collaboration based on these princi-
ples will provide an excellent opportunity to explore the influence
of culture and values in the path from scientific evidence to the
final recommendation, and ultimately to patterns of practice.
This will lead to a better understanding of the key elements in
the guideline development process, and the impact of social,
ethical and cultural issues on the effective dissemination and use of
CPGs.
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